top of page

Recent Posts

Search

CRISPR Plus Drug Treatment Makes Neuroblastoma Responsive to Immunotherapy

OPACC
Oct 29, 2024
1 min read

Researchers in Italy and Australia report a triple combination strategy involving CRISPR that boosts the response of neuroblastoma to immunotherapy.

Read more: https://crisprmedicinenews.com/news/crispr-plus-drug-treatment-makes-neuroblastoma-responsive-to-immunotherapy/

Recent Posts

Sex and Age May Influence Comorbidities in Pediatric ALL

While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...

FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...

Untreated GHD Linked to Adverse Outcomes in Childhood Cancer Survivors

Untreated growth hormone deficiency was associated with neurocognitive impairment and reduced physical functioning among adult survivors...

Comments

Sex and Age May Influence Comorbidities in Pediatric ALL

FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer

Untreated GHD Linked to Adverse Outcomes in Childhood Cancer Survivors

Trial Shows Targeted Treatment for Childhood Brain Tumor is Safe

New approach speeds up personalized cancer treatment for young patients

Motor Deficits in Children Off Therapy for Acute Lymphoblastic Leukemia

Boys with cancer can face infertility as adults. Can storing their stem cells help?

HRD HSCT Shows Promise Among Pediatric Patients With Hematologic Cancers

Treating a deadly childhood cancer with a sideways approach

Childhood Cancer Survivors Have Higher Risk of Chronic Conditions, Early Death

Archive

Search By Tags

bottom of page